Galectin Therapeutics (GALT) Shares Outstanding (2010 - 2026)

Galectin Therapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $65.9 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 4.05% year-over-year to $65.9 million; the TTM figure through Mar 2026 stood at $65.9 million (up 4.05% YoY), while the FY2025 annual figure was $65.2 million, up 3.24% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $65.9 million, up from $65.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $65.9 million in Q1 2026, with the low at $59.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $62.1 million (2024), against an average of $62.0 million.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) grew 0.14% in 2022, then grew 4.52% in 2024.
• Galectin Therapeutics' Shares Outstanding (Entity) stood at $59.4 million in 2022, then advanced by 4.08% to $61.9 million in 2023, then advanced by 2.11% to $63.2 million in 2024, then climbed by 3.24% to $65.2 million in 2025, then climbed by 1.0% to $65.9 million in 2026.
• Business Quant data shows GALT's Shares Outstanding (Entity) at $65.9 million in Q1 2026, $65.2 million in Q4 2025, and $64.5 million in Q3 2025.